DAFTAR PUSTAKA

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *68*(6), 394–424. https://doi.org/10.3322/caac.21492

Chan, B. A., & Hughes, B. G. M. (2015). Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. *Translational Lung Cancer Research*, *4*(1). https://tlcr.amegroups.com/article/view/2699

Chen, X., Du, J., Jiang, R., & Li, L. (2018). MicroRNA-214 inhibits the proliferation and invasion of lung carcinoma cells by targeting JAK1. *American Journal of Translational Research*, *10*(4), 1164–1171.

Dong, J., Li, B., Lin, D., Zhou, Q., & Huang, D. (2019). Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. *Frontiers in Pharmacology*, *10*, 230. https://doi.org/10.3389/fphar.2019.00230

Fan, X., Wang, X., Zhang, M., Deng, H., & Liu, Y. (2020). Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC. *Pathology - Research and Practice*, *216*(1), 152783. https://doi.org/10.1016/j.prp.2019.152783

Ferreiro, L., Suárez-Antelo, J., Álvarez-Dobaño, J. M., Toubes, M. E., Riveiro, V., & Valdés, L. (2020). Malignant Pleural Effusion: Diagnosis and Management. *Canadian Respiratory Journal*, *2020*, 2950751. https://doi.org/10.1155/2020/2950751

Florczuk, M., Szpechcinski, A., & Chorostowska-Wynimko, J. (2017). miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. *Targeted Oncology*, *12*(2), 179–200. https://doi.org/10.1007/s11523-017-0478-5

Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015). Non-small-cell lung cancer.

Nature Reviews Disease Primers, *1*(1), 15009. https://doi.org/10.1038/nrdp.2015.9

Han, F., He, J., Li, F., Yang, J., Wei, J., Cho, W., & Liu, X. (2015). Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer. *Biomed Research International*, *2015*, 672759–672759. https://doi.org/10.1155/2015/672759

Hsu, P.-C., Jablons, D. M., Yang, C.-T., & You, L. (2019). Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). *International Journal of Molecular Sciences*, *20*(15), 3821. https://doi.org/10.3390/ijms20153821

Inamura, K. (2017). Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. *Cells*, *6*(2), E12. https://doi.org/10.3390/cells6020012

Khan, J., Lieberman, J. A., & Lockwood, C. M. (2017). Variability in, variability out: Best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs. *Clinical Chemistry and Laboratory Medicine*, *55*(5), 608–621. Scopus. https://doi.org/10.1515/cclm-2016-0471

Kohno, T., Nakaoku, T., Tsuta, K., Tsuchihara, K., Matsumoto, S., Yoh, K., & Goto, K. (2015). Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. *Translational Lung Cancer Research*, *4*(2), 156–164. https://doi.org/10.3978/j.issn.2218-6751.2014.11.11

Lantuejoul, S., Rouquette, I., Brambilla, E., & Travis, W. D. (2016). [New WHO classification of lung adenocarcinoma and preneoplasia]. *Annales De Pathologie*, *36*(1), 5–14. https://doi.org/10.1016/j.annpat.2015.11.010

Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005). TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. *Cancer Research*, *65*(12), 5076–5083. https://doi.org/10.1158/0008-5472.CAN-05-0551

Liao, J., Lin, J., Lin, D., Zou, C., Kurata, J., Lin, R., He, Z., & Su, Y. (2017). Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. *Scientific Reports*, *7*(1), 781. https://doi.org/10.1038/s41598-017-00901-6

Long, H., Wang, Z., Chen, J., Xiang, T., Li, Q., Diao, X., & Zhu, B. (2015). MicroRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). *Oncotarget*, *6*(36), 38705–38718. https://doi.org/10.18632/oncotarget.5478

Meza, R., Meernik, C., Jeon, J., & Cote, M. L. (2015). Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. *PloS One*, *10*(3), e0121323. https://doi.org/10.1371/journal.pone.0121323

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T., Horn, L., Ramalingam, S. S., Rudin, C. M., Salgia, R., Sequist, L. V., Shaw, A. T., Simon, G. R., Somaiah, N., Spigel, D. R., … Govindan, R. (2015). Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, *10*(1 Suppl 1), S1-63. https://doi.org/10.1097/JTO.0000000000000405

Myers, D. J., & Wallen, J. M. (2021). Lung Adenocarcinoma. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK519578/

Oh, S., Ronaghi, R., & Cai, G. (2019). Molecular Testing on Pleural Fluid Samples. *Seminars in Respiratory and Critical Care Medicine*, *40*(03), 340–346. https://doi.org/10.1055/s-0039-1695702

Paris, C., Clement-Duchene, C., Vignaud, J. M., Gislard, A., Stoufflet, A., Bertrand, O., Thiberville, L., Grosdidier, G., Martinet, Y., Benichou, J., & Hainaut, P. (2010). Relationships between lung adenocarcinoma and gender, age, smoking and occupational risk factors: A case–case study. *Lung Cancer*, *68*(2), 146–153. https://doi.org/10.1016/j.lungcan.2009.06.007

Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., Felip, E., & ESMO Guidelines Working Group. (2012). Metastatic non-small-cell lung cancer

(NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, *23 Suppl 7*, vii56-64. https://doi.org/10.1093/annonc/mds226

Rolfo, C., Castiglia, M., Perez, A., Reclusa, P., Pauwels, P., Sober, L., Passiglia, F., & Russo, A. (2017). Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC). In A. Russo, A. Giordano, & C. Rolfo (Eds.), *Liquid Biopsy in Cancer Patients* (pp. 103–115). Springer International Publishing. https://doi.org/10.1007/978-3-319-55661-1_12

Sharma, T., Hamilton, R., & Mandal, C. C. (2015). miR-214: A potential biomarker and therapeutic for different cancers. *Future Oncology*, *11*(2), 349–363. https://doi.org/10.2217/fon.14.193

Shidham, V. B., & Atkinson, B. F. (2007). *Cytopathologic diagnosis of serous fluids*. Saunders/Elsevier. http://site.ebrary.com/id/10422779

Shin, Y. M., Jieun Yun, Ok-Jun Lee, Hye-Suk Han, Lim, S.-N., An, J. Y., Lee, K. H., Lee, K. M., & Choe, K. H. (2014). Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion. *Cancer Research and Treatment*, *46*(2), 178–185. https://doi.org/10.4143/crt.2014.46.2.178

Szpechcinski, A., Florczuk, M., Duk, K., Zdral, A., Rudzinski, S., Bryl, M., Czyzewicz, G., Rudzinski, P., Kupis, W., Wojda, E., Giedronowicz, D., Langfort, R., Barinow-Wojewodzki, A., Orlowski, T., & Chorostowska-Wynimko, J. (2019). The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. *Cellular and Molecular Life Sciences*, *76*(18), 3641–3656. https://doi.org/10.1007/s00018-019-03089-2

Travis, W., Brambilla, E., Burke, A., Marx, A., & Nicholson, A. (2015). *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart*. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Lung-Pleura-Thymus-And-Heart-2015

Underwood, C. I. M., Musick, A., & Glass, C. (2019, June 6). *Adenocarcinoma overview*. https://www.pathologyoutlines.com/topic/lungtumoradenocarcinoma.html

Vasef, M. A., Auerbach, A., Czuchlewski, D. R., Bocklage, T., Chabot-Richards, D., Aguilera, N., & Karner, K. H. (Eds.). (2016). *Diagnostic pathology: Molecular oncology: get full access and more at ExpertConsult.com*. Elsevier.

Wang, Y.-H., Zhu, Z.-R., Tong, D., Zhou, R., Xiao, K., & Peng, L. (2021). MicroRNAs and Lung Cancer: A Review Focused on Targeted Genes. *Exploratory Research and Hypothesis in Medicine*, *000*(000), 1–10. https://doi.org/10.14218/ERHM.2020.00058

Wang, Y.-S., Wang, Y.-H., Xia, H.-P., Zhou, S.-W., Schmid-Bindert, G., & Zhou, C.-C. (2012). MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. *Asian Pacific Journal of Cancer Prevention: APJCP*, *13*(1), 255–260. https://doi.org/10.7314/apjcp.2012.13.1.255

Wojczakowski, W., Kobylarek, D., Lindner, J., Limphaibool, N., & Kaczmarek, M. (2019). MicroRNAs – novel biomarkers for malignant pleural effusions. *Contemporary Oncology*, *23*(3), 133–140. https://doi.org/10.5114/wo.2019.89241

Zhang, J., & Wu, J. (2021). The Potential Roles of Exosomal miR-214 in Bone Metastasis of Lung Adenocarcinoma. *Frontiers in Oncology*, *10*. https://doi.org/10.3389/fonc.2020.611054

Zhang, K., Zhang, M., Jiang, H., Liu, F., Liu, H., & Li, Y. (2018). Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2. *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*, *105*, 545–552. https://doi.org/10.1016/j.biopha.2018.06.009

Zhang, Y.-L., Yuan, J.-Q., Wang, K.-F., Fu, X.-H., Han, X.-R., Threapleton, D., Yang, Z.-Y., Mao, C., & Tang, J.-L. (2016). The prevalence of EGFR

mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. *Oncotarget*, *7*(48), 78985–78993. https://doi.org/10.18632/oncotarget.12587

Zhao, C., Xu, Y., Zhang, Y., Tan, W., Xue, J., Yang, Z., Zhang, Y., Lu, Y., & Hu, X. (2013). Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. *Oncology Reports*, *30*(5), 2027–2034. https://doi.org/10.3892/or.2013.2728